201 related articles for article (PubMed ID: 23103352)
1. Clinical significance of zoledronic acid and strontium-89 in patients with asymptomatic bone metastases from non-small-cell lung cancer.
Wang Y; Tao H; Yu X; Wang Z; Wang M
Clin Lung Cancer; 2013 May; 14(3):254-60. PubMed ID: 23103352
[TBL] [Abstract][Full Text] [Related]
2. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial.
Rosen LS; Gordon D; Tchekmedyian NS; Yanagihara R; Hirsh V; Krzakowski M; Pawlicki M; De Souza P; Zheng M; Urbanowitz G; Reitsma D; Seaman J
Cancer; 2004 Jun; 100(12):2613-21. PubMed ID: 15197804
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of zoledronic acid in the management of skeletal metastases in patients with lung cancer in France, Germany, Portugal, the Netherlands, and the United kingdom.
Joshi AD; Carter JA; Botteman MF; Kaura S
Clin Ther; 2011 Mar; 33(3):291-304.e8. PubMed ID: 21600384
[TBL] [Abstract][Full Text] [Related]
4. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
Henry DH; Costa L; Goldwasser F; Hirsh V; Hungria V; Prausova J; Scagliotti GV; Sleeboom H; Spencer A; Vadhan-Raj S; von Moos R; Willenbacher W; Woll PJ; Wang J; Jiang Q; Jun S; Dansey R; Yeh H
J Clin Oncol; 2011 Mar; 29(9):1125-32. PubMed ID: 21343556
[TBL] [Abstract][Full Text] [Related]
5. Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan.
Henk HJ; Kaura S
J Med Econ; 2012; 15(1):175-84. PubMed ID: 22017235
[TBL] [Abstract][Full Text] [Related]
6. Impact of denosumab use on the survival of untreated non-squamous non-small cell lung cancer patients with bone metastases.
Udagawa H; Niho S; Kirita K; Umemura S; Matsumoto S; Yoh K; Goto K
J Cancer Res Clin Oncol; 2017 Jun; 143(6):1075-1082. PubMed ID: 28220258
[TBL] [Abstract][Full Text] [Related]
7. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study.
Scagliotti GV; Hirsh V; Siena S; Henry DH; Woll PJ; Manegold C; Solal-Celigny P; Rodriguez G; Krzakowski M; Mehta ND; Lipton L; García-Sáenz JA; Pereira JR; Prabhash K; Ciuleanu TE; Kanarev V; Wang H; Balakumaran A; Jacobs I
J Thorac Oncol; 2012 Dec; 7(12):1823-1829. PubMed ID: 23154554
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
Stopeck A; Rader M; Henry D; Danese M; Halperin M; Cong Z; Qian Y; Dansey R; Chung K
J Med Econ; 2012; 15(4):712-23. PubMed ID: 22409231
[TBL] [Abstract][Full Text] [Related]
9. Under usage of zoledronic acid in non-small cell lung cancer patients with metastatic bone disease--a short communication.
Calderone R; Nimako K; Leary A; Popat S; O'Brien ME
Eur J Cancer; 2011 Jul; 47(11):1603-5. PubMed ID: 21684152
[TBL] [Abstract][Full Text] [Related]
10. TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer.
James N; Pirrie S; Pope A; Barton D; Andronis L; Goranitis I; Collins S; McLaren D; O'Sullivan J; Parker C; Porfiri E; Staffurth J; Stanley A; Wylie J; Beesley S; Birtle A; Brown J; Chakraborti P; Russell M; Billingham L
Health Technol Assess; 2016 Jul; 20(53):1-288. PubMed ID: 27434595
[TBL] [Abstract][Full Text] [Related]
11. The potential application of zoledronic acid as anticancer therapy in patients with non-small-cell lung cancer.
Mahtani R; Khan R; Jahanzeb M
Clin Lung Cancer; 2011 Jan; 12(1):26-32. PubMed ID: 21273176
[TBL] [Abstract][Full Text] [Related]
12. Positive effects of zoledronate on skeletal-related events in patients with renal cell cancer and bone metastases.
Tunn UW; Stenzl A; Schultze-Seemann W; Strauss A; Kindler M; Miller K; Wirth MP; Zantl N; Schulze M; May C; Ruebel A; Birkholz K; Gruenwald V
Can J Urol; 2012 Jun; 19(3):6261-7. PubMed ID: 22704310
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for skeletal-related events in patients with non-small cell lung cancer treated by chemotherapy.
Sekine I; Nokihara H; Yamamoto N; Kunitoh H; Ohe Y; Tamura T
Lung Cancer; 2009 Aug; 65(2):219-22. PubMed ID: 19081161
[TBL] [Abstract][Full Text] [Related]
14. Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications.
Hirsh V; Tchekmedyian NS; Rosen LS; Zheng M; Hei YJ
Clin Lung Cancer; 2004 Nov; 6(3):170-4. PubMed ID: 15555218
[TBL] [Abstract][Full Text] [Related]
15. Meta-analysis comparing denosumab and zoledronic acid for treatment of bone metastases in patients with advanced solid tumours.
Zheng GZ; Chang B; Lin FX; Xie D; Hu QX; Yu GY; Du SX; Li XD
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 27430483
[TBL] [Abstract][Full Text] [Related]
16. The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis.
Zarogoulidis K; Boutsikou E; Zarogoulidis P; Eleftheriadou E; Kontakiotis T; Lithoxopoulou H; Tzanakakis G; Kanakis I; Karamanos NK
Int J Cancer; 2009 Oct; 125(7):1705-9. PubMed ID: 19521984
[TBL] [Abstract][Full Text] [Related]
17. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group.
Rosen LS; Gordon D; Tchekmedyian S; Yanagihara R; Hirsh V; Krzakowski M; Pawlicki M; de Souza P; Zheng M; Urbanowitz G; Reitsma D; Seaman JJ
J Clin Oncol; 2003 Aug; 21(16):3150-7. PubMed ID: 12915606
[TBL] [Abstract][Full Text] [Related]
18. Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases.
Saad F; Chen YM; Gleason DM; Chin J
Clin Genitourin Cancer; 2007 Sep; 5(6):390-6. PubMed ID: 17956712
[TBL] [Abstract][Full Text] [Related]
19. Zoledronic acid in the treatment of bone metastases from differentiated thyroid carcinoma.
Orita Y; Sugitani I; Toda K; Manabe J; Fujimoto Y
Thyroid; 2011 Jan; 21(1):31-5. PubMed ID: 21058881
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of bevacizumab-containing chemotherapy for non-squamous non-small cell lung cancer with bone metastases.
Tokito T; Shukuya T; Akamatsu H; Taira T; Ono A; Kenmotsu H; Naito T; Murakami H; Takahashi T; Endo M; Yamamoto N
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1493-8. PubMed ID: 23532208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
